Skip to main content
Fig. 4 | Cancer Imaging

Fig. 4

From: Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study

Fig. 4

Kaplan–Meier survival curves. A OS between normal-dose and reduced-dose subgroup in the TACE-apatinib; B OS between normal-dose and reduced-dose subgroup in the TACE-sorafenib; C OS in the normal-dose subgroup between TACE–apatinib and TACE-Sorafenib; D OS in the reduced-dose subgroup between TACE–apatinib and TACE-Sorafenib

Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us